160 related articles for article (PubMed ID: 14687450)
1. Disintegration/dissolution profiles of copies of Fosamax (alendronate).
Epstein S; Cryer B; Ragi S; Zanchetta JR; Walliser J; Chow J; Johnson MA; Leyes AE
Curr Med Res Opin; 2003; 19(8):781-9. PubMed ID: 14687450
[TBL] [Abstract][Full Text] [Related]
2. Comment on Disintegration/dissolution profiles of copies of Fosamax (alendronate).
Bolaños Díaz R
Curr Med Res Opin; 2004 Jul; 20(7):1035-6; author reply 1036-7. PubMed ID: 15265248
[No Abstract] [Full Text] [Related]
3. Comparative in vitro study of oesophageal adhesiveness of different commercial formulations containing alendronate.
Shakweh M; Bravo-Osuna I; Ponchel G
Eur J Pharm Sci; 2007 Aug; 31(5):262-70. PubMed ID: 17576054
[TBL] [Abstract][Full Text] [Related]
4. In vitro disintegration and dissolution studies of once-weekly copies of alendronate sodium tablets (70 mg) and in vivo implications.
Dansereau RJ; Crail DJ; Perkins AC
Curr Med Res Opin; 2008 Apr; 24(4):1137-45. PubMed ID: 18334082
[TBL] [Abstract][Full Text] [Related]
5. In vitro disintegration studies of weekly generic alendronate sodium tablets (70 mg) available in the US.
Dansereau RJ; Crail DJ; Perkins AC
Curr Med Res Opin; 2009 Feb; 25(2):449-52. PubMed ID: 19192989
[TBL] [Abstract][Full Text] [Related]
6. Is there variability in drug release and physical characteristics of amiodarone chloride from different commercially available tablets? Possible therapeutic implications.
Ngo SN; Barnes T
Int J Pharm Pract; 2010 Aug; 18(4):245-8. PubMed ID: 20636678
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo equivalence studies of alendronate monosodium tablets.
Roldán EJ; Quattrocchi O; Zanetti D; Piccinni E; Tessler J; Caballero LE; Lloret AP
Arzneimittelforschung; 2005; 55(2):93-101. PubMed ID: 15787276
[TBL] [Abstract][Full Text] [Related]
8. Comparison of simvastatin tablets from the US and international markets obtained via the Internet.
Veronin MA; Nguyen NT
Ann Pharmacother; 2008 May; 42(5):613-20. PubMed ID: 18413690
[TBL] [Abstract][Full Text] [Related]
9. In vitro determination of the release of alendronic acid from alendronate tablets of different brands during deglutition.
Lamprecht G
J Pharm Sci; 2009 Oct; 98(10):3575-81. PubMed ID: 19630066
[TBL] [Abstract][Full Text] [Related]
10. In vitro disintegration studies of weekly generic and branded risedronate sodium formulations available in Canada.
Walker AD; Adachi JD
Curr Med Res Opin; 2011 Sep; 27(9):1749-54. PubMed ID: 21781014
[TBL] [Abstract][Full Text] [Related]
11. [Esophagitis associated with use of alendronate in 5 postmenopausic patients].
Luciani J; Pigatto V; Naves A; Fay M; Silvestre Begnis M; Piola JC; Prada DB; Pedrana R
Acta Gastroenterol Latinoam; 2001 May; 31(2):59-63. PubMed ID: 11471319
[TBL] [Abstract][Full Text] [Related]
12. Esophageal transit and in vivo disintegration of branded risedronate sodium tablets and two generic formulations of alendronic acid tablets: a single-center, single-blind, six-period crossover study in healthy female subjects.
Perkins AC; Blackshaw PE; Hay PD; Lawes SC; Atherton CT; Dansereau RJ; Wagner LK; Schnell DJ; Spiller RC
Clin Ther; 2008 May; 30(5):834-44. PubMed ID: 18555931
[TBL] [Abstract][Full Text] [Related]
13. Multiple level C in vitro/in vivo correlation of dissolution profiles of two L-thyroxine tablets with pharmacokinetics data obtained from patients treated for hypothyroidism.
Volpato NM; Silva RL; Brito AP; Gonçalves JC; Vaisman M; Noël F
Eur J Pharm Sci; 2004 Apr; 21(5):655-60. PubMed ID: 15066666
[TBL] [Abstract][Full Text] [Related]
14. In vitro bioequivalence study of nine brands of artesunate tablets marketed in Nigeria.
Esimone CO; Okoye FB; Onah BU; Nworu CS; Omeje EO
J Vector Borne Dis; 2008 Mar; 45(1):60-5. PubMed ID: 18399319
[TBL] [Abstract][Full Text] [Related]
15. Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled, exploratory study.
Adachi JD; Faraawi RY; O'Mahony MF; Nayar A; Massaad R; Evans JK; Yacik C
Clin Ther; 2009 Aug; 31(8):1747-53. PubMed ID: 19808133
[TBL] [Abstract][Full Text] [Related]
16. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
[TBL] [Abstract][Full Text] [Related]
17. Clinical bioavaiability of nitrofurantoin--a case of bioinequivalence.
DiSanto AR; Chodos DJ; Phillips JP; DeSante KA; Stoll RG
Int J Clin Pharmacol Biopharm; 1976 Apr; 13(3):220-7. PubMed ID: 950266
[TBL] [Abstract][Full Text] [Related]
18. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International.
Sambrook PN; Geusens P; Ribot C; Solimano JA; Ferrer-Barriendos J; Gaines K; Verbruggen N; Melton ME
J Intern Med; 2004 Apr; 255(4):503-11. PubMed ID: 15049885
[TBL] [Abstract][Full Text] [Related]
19. Process analytical technology to understand the disintegration behavior of alendronate sodium tablets.
Xu X; Gupta A; Sayeed VA; Khan MA
J Pharm Sci; 2013 May; 102(5):1513-23. PubMed ID: 23450666
[TBL] [Abstract][Full Text] [Related]
20. Bioavailability and bioequivalence of two oral formulations of alendronate sodium 70 mg: an open-label, randomized, two-period crossover comparison in healthy Korean adult male volunteers.
Rhim SY; Park JH; Park YS; Lee MH; Kim DS; Shaw LM; Yang SC; Kang JS
Clin Ther; 2009 May; 31(5):1037-45. PubMed ID: 19539104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
